Medivation To Host Conference Call To Discuss Top-Line 12-Month Results From Dimebon(TM) Alzheimer's Disease Study

Medivation, Inc.
(Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30
a.m. Eastern time on Monday, June 11, to discuss top-line 12-month results
from its randomized, double-blind, placebo-controlled Phase 2 clinical
trial of Dimebon(TM), its lead product candidate, in Alzheimer's disease.



Rachelle Doody, M.D., Ph.D., lead investigator for the study, will
present the 12-month results for the first time at a scientific meeting at
the 2007 Alzheimer's Association International Conference on Prevention of
Dementia in Washington, D.C. Dr. Doody will present the data (abstract
#S3-02-03, "Results of a One-Year Randomized, Placebo-Controlled Trial of
Dimebon for the Treatment of Mild to Moderate Alzheimer's Disease") on
Tuesday, June 12, at 10:00 a.m. Eastern time during the symposium session
on "Emerging Compounds." Dr. Doody holds the Effie Marie Cain Chair in
Alzheimer's Disease Research at the Alzheimer's Disease and Memory
Disorders Center, Baylor College of Medicine in Houston.



The Alzheimer's Association, sponsor of the Prevention of Dementia
conference, has selected the Dimebon data for inclusion in a news briefing
to be held during the conference. That news briefing, which will focus on
Alzheimer's disease therapies and be open to credentialed reporters,
writers or editors from recognized external print, broadcast, syndicated or
online news organizations, will take place at 12:00 p.m. Eastern time on
Monday, June 11.




About Medivation



Medivation, Inc. is a biopharmaceutical company that acquires promising
technologies in the late preclinical development phase and develops them
quickly and cost-effectively. Medivation's current portfolio consists of
small molecule drugs in development to treat three large, unmet medical
needs -- Alzheimer's disease, Huntington's disease and hormone-refractory
prostate cancer. The Company intends to build and maintain a portfolio of
four to six development programs at all times. For more information, please
go to medivation.



This press release contains forward-looking statements, which are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ significantly from
those projected. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this
release. You are also cautioned that none of the Company's product
candidates has been approved for sale, that significant additional animal
and human testing is required in order to seek marketing approval for any
of its product candidates, and that Medivation cannot assure you that
marketing approval can be obtained for any of its product candidates.
Medivation's filings with the Securities and Exchange Commission, including
its Annual Report on Form 10-KSB for the year ended December 31, 2006,
include more information about factors that could affect the Company's
financial and operating results.


Medivation, Inc.

medivation